Roche presents fenebrutinib Phase III MS data at MSToronto2026

Roche has presented a broad package of Phase III neuroimmunology data at MSToronto2026, the joint ACTRIMS-ECTRIMS meeting held in Toronto from 21 to 23 October, spanning its investigational BTK inhibitor fenebrutinib and two approved medicines, Ocrevus and Enspryng. The data set, spread across more than 40 abstracts, is the largest the Basel-headquartered group has tabled in the neuroinflammation space to date.

The headline result centres on fenebrutinib, which Roche is positioning as a potential oral high-efficacy option for both relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Pooled data from the FENhance 1 and 2 pivotal trials showed a 55% reduction in annualised relapse rate versus teriflunomide (p less than 0.001) over 96 weeks. Separately, 75% of fenebrutinib-treated patients in the RMS pooled cohort achieved no evidence of disease activity on the NEDA-3 composite measure, a 70% reduction against the comparator.

Chronic lesion data draw attention

The most scientifically notable finding, selected as a late-breaking oral presentation at the meeting, concerns chronic active lesions. Roche reported that fenebrutinib reduced the volume of slowly expanding lesions by up to 30% in both RMS and PPMS patients, alongside a 62% reduction in accumulation of paramagnetic rim lesions in RMS, each result statistically significant against the active comparator. The company described this as the first prospective demonstration of a therapeutic effect on chronic active lesions in Phase III MS trials.

Chronic active lesions are a recognised correlate of long-term disability progression that most approved MS therapies do not adequately address. The ability of a once-daily oral agent to act on this mechanism, which requires CNS penetration, has been a major research focus across the industry. Fenebrutinib is a non-covalent, reversible BTK inhibitor designed to cross the blood-brain barrier and to suppress both peripheral B cells and intracranial microglia. Several covalent BTK inhibitors have previously struggled with CNS penetrance or tolerability in MS programmes, giving Roche's dataset added significance for the field if the findings are replicated after regulatory scrutiny.

Approved portfolio also extends its evidence base

Data for Ocrevus extended its evidence base into paediatric patients, following European Commission approval on 15 October for children aged 10 to 17, itself following FDA approval in May. Two-year OPERETTA 2 data showed that 90% of children in that age range with relapsing-remitting MS remained relapse-free, with B-cell depletion selective and childhood vaccine seropositivity preserved in 81 to 100% of patients. In older adults, the Phase IIIb CONSONANCE study showed 53% of participants over 55 years old remained free of disability progression at two years, comparable to younger cohorts.

Enspryng, the IL-6 receptor inhibitor developed by Roche subsidiary Chugai, produced exploratory METEOROID data in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), showing numerically superior relapse recovery versus placebo on the EDSS scale. An FDA decision on the first approved indication for Enspryng in MOGAD is expected in January 2027.

The competitive MS landscape is well-populated at the high-efficacy end, with natalizumab, alemtuzumab and anti-CD20 agents including ofatumumab and Roche's own Ocrevus occupying the market. An oral agent with a comparable or superior efficacy profile would represent a meaningful commercial opportunity; analysts will await the full safety disclosure from the FENhance and FENtrepid trials and any regulatory submission timeline from Roche before revising forecasts. Levi Garraway, Roche's chief medical officer, said the data indicate that fenebrutinib can "inhibit disease activity inside and outside the central nervous system", though the company has not yet announced a filing date in any jurisdiction.